Results 1 to 10 of about 129,195 (289)

Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers [PDF]

Gynecologic Oncology Reports
Objectives: To compare survival between gynecologic cancer patients with carboplatin hypersensitivity thereafter managed with carboplatin desensitization, cisplatin replacement, and alternative non-platinum therapy.
Nikita Bastin, Halle Petrie, Marc Robinson, Amir Javid, Robin Lane, Taryn Boucher, Alaina J. Brown, Lauren S. Prescott, Elizabeth Phillips, Ronald D. Alvarez, Marta Crispens, Cosby A. Stone   +11 more
doaj   +2 more sources

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Obgynia, 2023
Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB.
Nagusman Danil, Sharvianty Arifuddin, Eddy Hartono, Nur Rakhmah, Ajardiana, Syahrul Rauf, Andi Alfian Zainuddin   +6 more
doaj   +1 more source

Perftoran® Inhibits Hypoxia-Associated Resistance in Lung Cancer Cells to Carboplatin

Frontiers in Pharmacology, 2022
Perftoran® (perfluorodecalin) is an oxygen carrier, and carboplatin is a common chemotherapy drug used worldwide for lung cancer treatment. Hypoxia is one of the factors that induce resistance of lung cancer cells to carboplatin.
Amira M. Gamal-Eldeen, Amani A. Alrehaili, Afaf Alharthi, Bassem M. Raafat   +3 more
doaj   +1 more source

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers

Scientific Reports, 2021
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking effective therapy. Many TNBCs show remarkable response to carboplatin-based chemotherapy, but often develop resistance over time.
Stijn Moens, Peihua Zhao, Maria Francesca Baietti, Oliviero Marinelli, Delphi Van Haver, Francis Impens, Giuseppe Floris, Elisabetta Marangoni, Patrick Neven, Daniela Annibali, Anna A. Sablina, Frédéric Amant   +11 more
doaj   +1 more source

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. [PDF]

PLoS ONE, 2017
Carboplatin is widely used to treat lung cancer in the United States as an alternative to cisplatin. Several studies have demonstrated that cisplatin-based regimen is associated with a high frequency of thromboembolic complications.
Eric S Kim, Andrea M Baran, Esther L Mondo, Thomas D Rodgers, Gradon C Nielsen, David W Dougherty, Kishan J Pandya, David Q Rich, Edwin van Wijngaarden   +8 more
doaj   +1 more source

Efficacy and Adverse Events of Carboplatin Desensitisation Therapy for Gynaecological Cancer: A Retrospective Study

Medicines, 2022
Background: Carboplatin, the key drug used in treating gynaecological cancer, has an approximately 12–16% risk of hypersensitivity reactions.
Akihito Yamamoto, Seiryu Kamoi, Shigeru Matsuda, Rieko Kawase, Kazuho Nakanishi, Shunji Suzuki   +5 more
doaj   +1 more source

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP

Cancer Medicine, 2023
Grade 3/4 anaemia, which is mainly induced by carboplatin, frequently occurs in patients treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). However, dose reduction of carboplatin may raise concerns about the oncological outcome.
Jung Hwan Ji, Soong June Bae, Seul‐Gi Kim, Min Hwan Kim, Gun‐Min Kim, Joohyuk Sohn, Joon Jeong, Jee Hung Kim, Sung Gwe Ahn   +8 more
doaj   +1 more source

Metastatic ameloblastoma with postoperative accelerated tumor growth treated with carboplatin and paclitaxel: a case report [PDF]

Kosin Medical Journal, 2022
Ameloblastoma is a histologically benign odontogenic epithelial tumor that rarely metastasizes. However, metastasis to the lungs can occur, usually years after the development of the primary tumor.
Joo Un Park, Jae Wan Jung
doaj   +1 more source

Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice

BMC Cancer, 2022
Background Carboplatin is the backbone cytotoxic agent for many chemotherapy regimens for lung cancer. Dosing of carboplatin is complicated due to its relationship to renal function and narrow therapeutic index.
Seçkin Akgül, Bryan A. Chan, Peter M. Manders   +2 more
doaj   +1 more source

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer [PDF]

, 2012
Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum-resistant disease ultimately occurs in most patients.
A Bali, C Beretta, D P Lovell, E Papacharalbous, E Rosenberg, G D’Andrilli, H M Coley, HM Coley, I-S Song, K Madhuri, MA Levesque, N A M Safuwan, N Syed, N Syed, P Chivers, P Vlachos, P Zhang, PS Larson, RM Glasspool, S Butler-Manuel, SH Wei, ST Kim, T Crook, T Giannopoulos, T Kobatake, V Masciullo, W Roeb, Y Ma   +27 more
core   +1 more source